Umecrine Cognition
Novel treatments for cognitive and sleep disorders
- CEO: Magnus Doverskog
- First investment year: 2016
- Fund: Partnerinvest North
- Business sector: Life Science

Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS. The company is focused on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease and for treatment of excessive daytime sleepiness in patients with idiopathic hypersomnia.